A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

The successful development of bortezomib-based therapy for treatment of multiple myeloma has established proteasome inhibition as an effective therapeutic strategy, and both 20S proteasome peptidases and 19S deubiquitinases (DUBs) are becoming attractive targets of cancer therapy. It has been report...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ningning, Liu, Chunjiao, Li, Xiaofen, Liao, Siyan, Song, Wenbin, Yang, Changshan, Zhao, Chong, Huang, Hongbiao, Guan, Lixia, Zhang, Peiquan, Liu, Shouting, Hua, Xianliang, Chen, Xin, Zhou, Ping, Lan, Xiaoying, Yi, Songgang, Wang, Shunqing, Wang, Xuejun, Dou, Q. Ping, Liu, Jinbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050382/
https://www.ncbi.nlm.nih.gov/pubmed/24912524
http://dx.doi.org/10.1038/srep05240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050382/
https://www.ncbi.nlm.nih.gov/pubmed/24912524
http://dx.doi.org/10.1038/srep05240

Ejemplares similares